ARS Pharmaceuticals (SPRY) Other financing activities (2020 - 2026)

ARS Pharmaceuticals has reported Other financing activities for 7 years, with the latest figure at $62000.0 in Q1 2026.

• Quarterly Other financing activities fell 91.45% year-over-year to $62000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 44.07% YoY) and the FY2025 annual result came in at $5.7 million, up 88.36% from the prior year.
• Other financing activities declined to $62000.0 in Q1 2026 per SPRY's latest filing, from $1.8 million in the prior quarter.
• Over five years, Other financing activities peaked at $2.9 million in Q2 2023 and troughed at $62000.0 in Q1 2026.
• A 5-year average of $1.1 million and a median of $725000.0 in 2025 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2026: Other financing activities jumped 894.43% in 2023, then slumped 91.45% in 2026.
• Over 5 years, Other financing activities stood at $283000.0 in 2022, then surged by 537.81% to $1.8 million in 2023, then declined by 15.07% to $1.5 million in 2024, then gained by 16.11% to $1.8 million in 2025, then plunged by 96.52% to $62000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $62000.0, $1.8 million, and $479000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.